Targeting MUC1‐C has been reported to inhibit TIGAR at the protein level in hematologic malignancies (Yin, Kosugi, & Kufe, 2012; Yin, Kufe, Avigan, & Kufe, 2014) and colon cancer (Ahmad et al., 2017). Here, TIGAR is linked to colonic neoplasm.